JSIAMA Biopharmaceuticals key facts
as of Oct 2026- Developer of clinical-stage biopharmaceuticals designed for innovative immunotherapies targeting respiratory diseases, including cancer.
- JSIAMA Biopharmaceuticals is valued at approximately $66.2M as of Oct 2026 (last reported valuation).
- It has raised $6.9M; the latest was Early Stage VC ($6.9M) in Mar 2025.
- Notable investors include Tailong VC, Prosperico Ventures, Zhejiang Hisun Pharmaceutical Company.
- Status: Privately Held (backing).
JSIAMA Biopharmaceuticals's last reported valuation, Mar 2025. Nothing priced has surfaced since.
- ·Watch JSIAMA Biopharmaceuticals: the Monday email on marks, rounds and moves
JSIAMA Biopharmaceuticals funding rounds
No funding rounds for JSIAMA Biopharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs JSIAMA Biopharmaceuticals
3JSIAMA Biopharmaceuticals valuation
JSIAMA Biopharmaceuticals's last reported valuation was $66.2 million in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.
JSIAMA Biopharmaceuticals investors
3 investors are on record for JSIAMA Biopharmaceuticals, including Tailong VC, Prosperico Ventures and Zhejiang Hisun Pharmaceutical Company.
About JSIAMA Biopharmaceuticals
Developer of clinical-stage biopharmaceuticals designed for innovative immunotherapies targeting respiratory diseases, including cancer. The company focuses on the discovery and development of novel drug platforms, providing healthcare professionals with therapeutic solutions for conditions like allergic rhinitis, allergic dermatitis, respiratory infections, and vaccine adjuvants.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2021
- Website
- iamabio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.